APO-FLUCONAZOLE TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Kaufe es jetzt

Fachinformation Fachinformation (SPC)
22-09-2023

Wirkstoff:

FLUCONAZOLE

Verfügbar ab:

APOTEX INC

ATC-Code:

J02AC01

INN (Internationale Bezeichnung):

FLUCONAZOLE

Dosierung:

50MG

Darreichungsform:

TABLET

Zusammensetzung:

FLUCONAZOLE 50MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

100

Verschreibungstyp:

Prescription

Therapiebereich:

AZOLES

Produktbesonderheiten:

Active ingredient group (AIG) number: 0122529001; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

1998-10-09

Fachinformation

                                _APO-FLUCONAZOLE (Fluconazole Tablets) _
_ _
_Page 1 of 56 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
APO-FLUCONAZOLE
Fluconazole Tablets
Tablets, 50 mg, 100 mg and 200 mg, oral
Apotex Standard
Antifungal Agent
APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
OCT 09, 1998
Date of Revision:
AUG 22, 2023
Submission Control Number: 274760
_APO-FLUCONAZOLE (Fluconazole Tablets) _
_ _
_Page 2 of 56 _
RECENT MAJOR LABEL CHANGES
7. WARNINGS AND PRECAUTIONS
11/2022
9. DRUG INTERACTIONS
08/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1 Pediatrics (<18 years of age)
...........................................................................................
4
1.2 Geriatrics
.........................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1 Dosing Considerations
.....................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
................................................................ 5
4.5 Missed Dose
....................................................................................................................
8
5
                                
                                Lesen Sie das vollständige Dokument
                                
                            

Dokumente in anderen Sprachen

Fachinformation Fachinformation Französisch 22-09-2023

Suchen Sie nach Benachrichtigungen zu diesem Produkt